Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 3 July

Grady Wulff
July 3, 2023

Weekly Wrap 30 June

Grady Wulff
June 30, 2023

Morning Bell 30 June

Sophia Mavridis
June 30, 2023

Morning Bell 29 June

Grady Wulff
June 29, 2023

Morning Bell 28 June

Grady Wulff
June 28, 2023

Morning Bell 27 June

Grady Wulff
June 27, 2023

Morning Bell 26 June

Grady Wulff
June 26, 2023

Weekly Wrap 23 June

Grady Wulff
June 23, 2023

Morning Bell 23 June

Sophia Mavridis
June 23, 2023

Morning Bell 22 June

Sophia Mavridis
June 22, 2023

Morning Bell 21 June

Grady Wulff
June 21, 2023

Morning Bell 20 June

Grady Wulff
June 20, 2023